

## Capital Health PHARMACY DEPARTMENT - Preliminary Investigational Drug Study Cost Estimate Official Estimate & Agreement

PLEASE NOTE: This is a preliminary budget only!! Subject to change. Official Estimate & Agreement will be drawn up once final Protocol version has received Ethics Approval

Clinical Trial Title:		
	Principal	
Protocol #	•	
DESCRIP	<u> </u>	TOTAL (\$)
1. Set-up/Close-out: Range from \$900 - \$1200 (depending on the complexity)		
Set-up Costs (\$600-\$900) may include, but are not limited to:		
•	Reviewing the protocol	
•	Preparing a dispensing binder	
•	Reviewing and receiving inventory	
•	Inservicing Pharmacy staff	
•	Initiation/set-up meetings	
•	Preparing accountability sheets	
Close-out Costs (\$300) may include, but are not limited to:		
•	Return of drugs and supplies or destruction	
•	Archiving	
•	Documentation and reconciliations	
•	Final billing	
•	Close-out visit	
2. Dispensing Costs: (dependant on complexity)		
•	Each dispensing for oral (or prepackaged) medication: \$15 - \$30/Rx	
•	Each dose/product requiring sterile manipulation: \$30 - \$70/each	
•	Randomization: \$10 - \$20/call or action (depending on complexity)	
3. Study Maintenance:		
•	While study is active (for maintenance of records and inventory, etc.)	
	<ul> <li>\$100/quarter (0-5 patients)</li> </ul>	
	o \$150/quarter (6-10 patients)	
	o <b>\$200/quarter</b> (11-20 patients)	
	o \$300/quarter (20+ patients)	
•	\$60 - Monitoring visits *Multiple days will be charged as multiple visits	
•	\$150/Audit	
•	\$150/Protocol amendment that requires a change in pharmacy procedures	
•	\$25/quarter for refrigerator/freezer maintenance (if applicable)	
		\$/callback (if
•	After-hours callback of Pharmacy staff @ \$200.00/callback for Pharmacist OR	applicable)+ All
	\$300.00/callback for Pharmacist + IV Trained Technician (subject to change as	unforeseen expenses
	per CDHA Collective Agreement)	required or requested
	Items not supplied by study sponsor, delivery charges, etc.	by sponsor/study staff
Total Estimate:		

Fee structure is subject to annual review